485 related articles for article (PubMed ID: 15102952)
1. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
2. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger.
Zhu H; Jia Z; Mahaney JE; Ross D; Misra HP; Trush MA; Li Y
Cardiovasc Toxicol; 2007; 7(3):202-11. PubMed ID: 17901563
[TBL] [Abstract][Full Text] [Related]
3. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
4. Evidence for NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated quinone-dependent redox cycling via plasma membrane electron transport: A sensitive cellular assay for NQO1.
Tan AS; Berridge MV
Free Radic Biol Med; 2010 Feb; 48(3):421-9. PubMed ID: 19932748
[TBL] [Abstract][Full Text] [Related]
5. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
[TBL] [Abstract][Full Text] [Related]
6. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
7. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
Qiu XB; Cadenas E
Arch Biochem Biophys; 1997 Oct; 346(2):241-51. PubMed ID: 9343371
[TBL] [Abstract][Full Text] [Related]
8. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
[TBL] [Abstract][Full Text] [Related]
10. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition.
Zafar KS; Siegel D; Ross D
Mol Pharmacol; 2006 Sep; 70(3):1079-86. PubMed ID: 16790533
[TBL] [Abstract][Full Text] [Related]
11. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
12. Dual effects of N-acetyl-L-cysteine dependent on NQO1 activity: suppressive or promotive of 9,10-phenanthrenequinone-induced toxicity.
Toyooka T; Shinmen T; Aarts JM; Ibuki Y
Toxicol Appl Pharmacol; 2012 Nov; 264(3):404-12. PubMed ID: 22925602
[TBL] [Abstract][Full Text] [Related]
13. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
[TBL] [Abstract][Full Text] [Related]
14. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
15. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
16. In vivo relevance of two critical levels for NAD(P)H:quinone oxidoreductase (NQO1)-mediated cellular protection against electrophile toxicity found in vitro.
de Haan LH; Pot GK; Aarts JM; Rietjens IM; Alink GM
Toxicol In Vitro; 2006 Aug; 20(5):594-600. PubMed ID: 16314070
[TBL] [Abstract][Full Text] [Related]
17. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK.
González-Aragón D; Alcaín FJ; Ariza J; Jódar L; Barbarroja N; López-Pedrera C; Villalba JM
Chem Biol Interact; 2010 Jul; 186(2):174-83. PubMed ID: 20433816
[TBL] [Abstract][Full Text] [Related]
18. Regeneration of lipophilic antioxidants by NAD(P)H:quinone oxidoreductase 1.
Bello RI; Kagan VE; Tyurin V; Navarro F; Alcaín FJ; Villalba JM
Protoplasma; 2003 May; 221(1-2):129-35. PubMed ID: 12768350
[TBL] [Abstract][Full Text] [Related]
19. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
